Romesh Kohli, MD
Nephrology · Buffalo, NYNPI 1730146978
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $401 of the $579 with a category attached, or 69.2%. Artivion, Inc. accounts for 69.2% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $401 and has fallen 92.3% since, to $31 in 2025. That places this record below the midpoint for nephrology clinicians in NY, where the typical reported total is $564.
Across 37 payments — averaging $15.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Artivion, Inc.$401
- Travere Therapeutics, Inc.$143
- Aurinia Pharma U.S., Inc.$20
- Amgen$15
What the payments were for
- Travel & lodging$40169%
- Food & beverage$153%
- Education$16328%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Artivion, Inc. | 1 | $401 |
| Travere Therapeutics, Inc. | 34 | $143 |
| Aurinia Pharma U.S., Inc. | 1 | $20 |
| Amgen | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- On-X$401
How this compares
$579 in reported general payments places this provider in the 50th percentile of 935 nephrology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 329 | $275,426 |
| EliquisApixaban | 85 | $74,040 |
| VelphoroSucroferric Oxyhydroxide | 21 | $65,716 |
| ProcritEpoetin Alfa | 27 | $58,750 |
| SpsSodium Polystyrene Sulfon/Sorb | 41 | $26,602 |
| Cinacalcet Hcl | 95 | $15,247 |
| RetacritEpoetin Alfa-Epbx | 25 | $14,163 |
| FarxigaDapagliflozin Propanediol | 16 | $12,151 |
| Sevelamer Carbonate | 85 | $11,385 |
| Sirolimus | 17 | $6,780 |
| Clonidine | 34 | $4,920 |
| Metoprolol Succinate | 148 | $4,152 |
| Rosuvastatin Calcium | 219 | $3,121 |
| Tacrolimus | 31 | $3,019 |
| Calcium Acetate | 40 | $2,977 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Buffalo
- Payam ShakouriPoughkeepsie$930K
- Gerald AppelNew York$842K
- Richard ChanNew York$514K
- Bruce SpinowitzBronx$465K
- Steven CocaNew York$445K
- Joseph RoglieriTroy$425K
- Jai RadhakrishnanNew York$369K
- Savneek ChughHawthorne$325K
- Gerard TepedinoManhasset$308K
- Frank CortazarAlbany$289K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.